- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT03378531
A Study of AEB1102 (Pegzilarginase) in Patients With Arginase 1 Deficiency
An Open-label, Multicentre Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of AEB1102 in Patients With Arginase 1 Deficiency
The purpose of this study is to determine the safety, tolerability, and efficacy of long-term intravenous and subcutaneous administration of pegzilarginase for the treatment of pediatric and adult patients with ARG1-D who complete Study CAEB1102-101A.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Purpose of this study is to determine the safety, tolerability, and efficacy of long-term intravenous and subcutaneous administration of pegzilarginase for the treatment of pediatric and adult patients with ARG1-D who complete Study CAEB1102-101A.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1X8
- The Hospital for Sick Children
-
-
-
-
-
Porto, Portogallo
- Centro Hospitalar S. Joao
-
-
-
-
-
London, Regno Unito
- Great Ormond Street Hospital
-
-
-
-
California
-
Stanford, California, Stati Uniti, 94305
- Stanford University School of Medicine
-
-
Florida
-
Gainsville, Florida, Stati Uniti, 32610
- University of Florida
-
-
New York
-
New York, New York, Stati Uniti, 10029
- Icahn School of Medicine at Mount Sinai
-
-
Texas
-
Dallas, Texas, Stati Uniti, 75390
- UTSW
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Complete treatment in Study CAEB1102-101A without experiencing any clinically significant adverse event or other unmanageable drug toxicity that would preclude continued dosing
- Confirmation by the Investigator and the Sponsor determine that it is acceptable for the patient to continue dosing with AEB1102
- If female and of child-bearing potential, has a negative serum pregnancy test within 7 days before enrollment
- If sexually active (male or female), must be surgically sterile, post-menopausal (female), or must agree to use a physician-approved method of birth control during the study and for a minimum of 30 days after the last study drug administration
- Patient or legal guardian is able and willing to provide written informed consent and where required assent, and to comply with all requirements of study participation (including all study procedures and continuation of prescribed diet without modification), prior to any screening procedures
Exclusion Criteria:
1. Clinically significant concurrent disease, serious intercurrent illness, or other extenuating circumstances
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: pegzilarginase (AEB1102)
Each patient may receive pegzilarginase administered IV or SC for up to 4 years. |
modified human arginase I
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Number of Participants With Treatment-related Adverse Events
Lasso di tempo: From start of study up to 262 weeks
|
From start of study up to 262 weeks
|
|
Number of Participants With Anti-pegzilarginase and Anti-PEG Antibodies
Lasso di tempo: From start of study up to 262 weeks
|
From start of study up to 262 weeks
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Plasma Arginine Levels
Lasso di tempo: From start of study up to 240 weeks
|
Change in plasma arginine concentrations from study Baseline |
From start of study up to 240 weeks
|
|
Plasma GC Levels (Argininic Acid)
Lasso di tempo: From start of study up to 240 weeks
|
Change in plasma argininic acid concentrations from study Baseline |
From start of study up to 240 weeks
|
|
Plasma GC Levels (Guanidinoacetic Acid)
Lasso di tempo: From start of study up to 240 weeks
|
Change in plasma guanidinoacetic acid concentrations from study Baseline |
From start of study up to 240 weeks
|
|
Plasma GC Levels (α-keto-δ-guanidinovaleric Acid)
Lasso di tempo: From start of study up to 240 weeks
|
Change in plasma α-keto-δ-guanidinovaleric acid concentrations from study Baseline |
From start of study up to 240 weeks
|
|
Plasma GC Levels (α-N-acetylarginine)
Lasso di tempo: From start of study up to 240 weeks
|
Change in plasma α-N-acetylarginine concentrations from study Baseline |
From start of study up to 240 weeks
|
|
Six-Minute Walk Test (6MWT)
Lasso di tempo: From start of study up to 262 weeks
|
Change in 6MWT distance from study Baseline |
From start of study up to 262 weeks
|
|
Gross Motor Function Measure (GMFM) Part D
Lasso di tempo: From start of study up to 262 weeks
|
Change from study Baseline. The GMFM-D evaluates the patient's ability to stand via assessment of 13 activities, each of which is scored on a scale of 0 to 3, with a scale range of 0-39 points. An increase in GMFM-D score indicates improvement in standing. |
From start of study up to 262 weeks
|
|
Gross Motor Function Measure (GMFM) Part E
Lasso di tempo: From start of study up to 262 weeks
|
Change from study Baseline. The GMFM-E evaluates a subject's ability to walk, run, and jump via assessment of 24 activities, each of which is scored on a scale of 0 to 3, , with a scale range of 0-72. A higher GMFM-E score indicates greater ability, with increasing scores indicating improvement in walking, running, and jumping. |
From start of study up to 262 weeks
|
|
Modified Ashworth Scale (MAS)
Lasso di tempo: From start of study up to 262 weeks
|
Spasticity improvement for lower body muscle groups based on MAS from study Baseline. The MAS is used to measure the resistance to passive movement about a joint due to spasticity using a 6-point scoring scale with possible values of 0, 1, 1+ (scored as 1.5), 2, 3, and 4, where 0 is no increase in muscle tone (no spasticity) and 4 is affected part(s) rigid in flexion or extension (total rigidity). Thus, a decrease in MAS score indicates improvement in spasticity. |
From start of study up to 262 weeks
|
|
Berg Balance Scale (BBS)
Lasso di tempo: From start of study up to 262 weeks
|
Change from study Baseline. The BBS, a measure of balance, utilizes a 5-point scoring scale of 0 (indicating the lowest level of function) to 4 (indicating the highest level of function) for 14 tasks, giving a scale range of 0-56, with a higher score representing better balance. |
From start of study up to 262 weeks
|
|
Purdue Pegboard Test (Dominant Hand)
Lasso di tempo: From start of study up to 262 weeks
|
Change from study Baseline. The Purdue Pegboard Test evaluates manipulative dexterity and bimanual coordination, measuring performance speed in a fine motor task via gross movements of the arms, hands, and fingers, as well as fine motor extremity dexterity. A higher Purdue Pegboard Test score indicates better dexterity and coordination. Scores were compared to normative data, compiled from healthy individuals, to produce a Z-score (0 being population mean). A positive Z-score indicates the raw score is higher than the mean average; a negative Z-score indicates the raw score is below the mean average. |
From start of study up to 262 weeks
|
|
Purdue Pegboard Test (Non-dominant Hand)
Lasso di tempo: From start of study up to 262 weeks
|
Change from study Baseline. The Purdue Pegboard Test evaluates manipulative dexterity and bimanual coordination, measuring performance speed in a fine motor task via gross movements of the arms, hands, and fingers, as well as fine motor extremity dexterity. A higher Purdue Pegboard Test score indicates better dexterity and coordination. Scores were compared to normative data, compiled from healthy individuals, to produce a Z-score (0 being population mean). A positive Z-score indicates the raw score is higher than the mean average; a negative Z-score indicates the raw score is below the mean average. |
From start of study up to 262 weeks
|
|
Number of Participants With Hyperammonemic Episodes
Lasso di tempo: From study start up to 262 weeks
|
Hyperammonemic episodes" are defined as either an AE for which an Investigator observed symptoms considered to be consistent with a "hyperammonemic episode", or an AE in a patient meeting all 3 of the following criteria: 1. Confirmed ammonia level ≥100 μM, 2. One or more symptoms related to hyperammonemia, 3. Requiring hospitalization or emergency room management. |
From study start up to 262 weeks
|
|
Number of Participants With Seizures
Lasso di tempo: From study start up to 262 weeks
|
From study start up to 262 weeks
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Direttore dello studio: Mattias Rudebeck, PhD MSc BMedSc, Immedica Pharma AB
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattie del cervello
- Malattie del sistema nervoso centrale
- Malattie del sistema nervoso
- Metabolismo, errori congeniti
- Malattie genetiche, congenite
- Malattie metaboliche
- Malattie cerebrali, metaboliche, congenite
- Malattie cerebrali, metaboliche
- Metabolismo degli aminoacidi, errori congeniti
- Disturbi del ciclo dell'urea, congeniti
- Malattie e anomalie congenite, ereditarie e neonatali
- Malattie nutrizionali e metaboliche
- Iperargininemia
Altri numeri di identificazione dello studio
- CAEB1102-102A
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .